The global type 2 diabetes market is anticipated to witness high growth owing to rising prevalence of obesity. Type 2 diabetes, also known as adult-onset diabetes, is a condition in which the body becomes resistant to the normal effects of insulin or gradually loses the capacity to produce enough insulin in the body. Insulin is important for regulating blood sugar, also called blood glucose. It helps glucose get into the body's cells to give them energy. With type 2 diabetes, the body either doesn't produce enough insulin or the cells ignore the insulin. This causes sugar to build up in the blood instead of being absorbed into the cells.

The global type 2 diabetes market is estimated to be valued at US$ 16.7 billion in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period from 2024 to 2031.

Obesity has been identified as a major risk factor for type 2 diabetes. It is estimated that nearly 90% of adults with type 2 diabetes are either overweight or obese. Rising prevalence of obesity due to sedentary lifestyles and unhealthy dietary habits has significantly contributed to the growing incidence of type 2 diabetes globally.

Key Takeaways

Key players operating in the type 2 diabetes market are Novo Nordisk, Sanofi, Eli Lilly and Company, AstraZeneca, Merck & Co. and Johnson & Johnson.

The key opportunities in the market include expansion in emerging economies, increasing awareness about diabetes management and development of novel treatment therapies. Emerging Asian countries with large population bases such as China and India present huge Type 2 Diabetes Market Growth potential for players in the type 2 diabetes market.

Globally, Asia Pacific region is expected to witness highest growth owing to rising obesity rates and changes towards sedentary lifestyle in countries like China, India and Indonesia. Leveraging the growth opportunities through partnerships with local players will help global companies to strengthen their presence in emerging markets.

Market Drivers

Rising prevalence of obesity is a major factor driving the growth of type 2 diabetes market. It is estimated that nearly 90% of adults with type 2 diabetes are overweight or obese. Growing obese population globally due to unhealthy eating habits and sedentary lifestyles has significantly contributed to the rising diabetes cases.

Market Restrains

High cost of diabetes care and medications pose a major challenge especially in developing regions. The lifetime healthcare expenditure for a person diagnosed with diabetes in their 40s is over $300,000 which significantly impacts the affordability of treatment. This remains a key restraint for the growth of type 2 diabetes market.

Segment Analysis

The global Type 2 Diabetes Market Regional Analysis is dominated by the oral medication segment owing to its ease of use and high efficiency. Oral anti-diabetic drugs include products like biguanides, sulfonylureas, DPP-4 inhibitors, SGLT-2 inhibitors and others which are widely prescribed depending on the severity of condition and other medical history of patients. Biguanides led the oral medication segment in 2024 attributed to the efficacy and affordable prices of metformin. However, DPP-4 inhibitors are expected to witness fastest growth during the forecast period due to rising number of new drug approvals and popularity of GLP analogs for their effectiveness in managing blood sugar levels.

Global Analysis

North America held the largest share of type 2 diabetes market in 2024 driven by rising prevalence of obesity and sedentary lifestyles among population. However, Asia Pacific is projected to register fastest growth till 2031 supported by expanding patient pool, growing health awareness and improving access to healthcare in countries like China and India. The revenue from China, Japan and India together is anticipated to surpass North America by 2028. Government initiatives to curb diabetes along with progressive incorporation of advanced drugs and devices will significantly contribute to the market expansion across Asia Pacific in the forecast timeline. Europe captures second largest revenue share with major revenue sources being Germany, UK and France while LAMEA will exhibit moderate growth through 2031.

Get more insights: Type 2 Diabetes Market

For More Insights Discover the Report In language that Resonates with you

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)